at 2153 has been researched along with Carcinoma, Lewis Lung in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, J; Lu, DY; Xu, B | 1 |
| Ding, J; Huang, M; Lu, DY; Xu, B; Xu, CH; Zhu, H | 1 |
2 other study(ies) available for at 2153 and Carcinoma, Lewis Lung
| Article | Year |
|---|---|
Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; China; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Razoxane; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
Medicinal chemistry of probimane and MST-16: comparison of anticancer effects between bisdioxopiperazines.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Mice; Mice, Nude; Molecular Structure; Piperazines; Razoxane; Structure-Activity Relationship; Time Factors; Xenograft Model Antitumor Assays | 2006 |